Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
523 stopped studies mapped to Lymphoid Leukemia and descendants · 86% state a reason
Over the 523 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06639958 | A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at… | N/A | suspended | Oct 15, 2024 | Children's Oncology Group | All potential pilot phase pts have been enrolled. | Enrollment / accrual |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed… | Phase 1 / Phase 2 | terminated | Sep 2, 2021 | M.D. Anderson Cancer Center | The study was terminated early due to slow enrollment. | Enrollment / accrual |
| NCT06009107 | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic…(B-ALL) | Phase 1 / Phase 2 | withdrawn | Aug 24, 2023 | Juventas Cell Therapy Ltd. | Sponsor changed product development plan | Other (stated, no rule matched) |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of… | Phase 1 | terminated | Apr 2, 2024 | Roswell Park Cancer Institute | Manufacturing issues | Drug supply |
| NCT04125290 | US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)(PROXY) | — | terminated | Oct 14, 2019 | AstraZeneca | Study stopped due to lack of recruitment. | Enrollment / accrual |
| NCT05879458 | Ritlecitinib in CTCL | Phase 2 | terminated | May 30, 2023 | Icahn School of Medicine at Mount Sinai | No significant improvement in disease as graded by our assessments. | Other (stated, no rule matched) |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | N/A | withdrawn | Aug 1, 2023 | Neena Kapoor, M.D. | No funding available. | Funding |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT06013904 | Difficult PIV Placement in the Pediatric ED | N/A | withdrawn | Aug 28, 2023 | University of Texas at Austin | The logistics of the study made it too challenging to conduct within a pediatric setting. | Other (stated, no rule matched) |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and… | Phase 1 | withdrawn | Aug 30, 2022 | Janssen Research & Development, LLC | Business Decision | Sponsor / business decision |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | Study was closed early due to low accrual and lack of response. | Enrollment / accrual |
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression…(BOSS) | Phase 2 | withdrawn | Feb 21, 2025 | AstraZeneca | AstraZeneca has made the decision to cancel the trial. | Other (stated, no rule matched) |
| NCT05292898 | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With… | Phase 1 | terminated | Mar 23, 2022 | Institute of Hematology & Blood Diseases Hospital, China | Achieve the proof of concept | Other (stated, no rule matched) |
| NCT05405309 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic…(CORONADO CLL) | Phase 1 / Phase 2 | terminated | Jun 6, 2022 | University of Utah | This study was terminated due to sponsor de-activation of all programs associated with RP-3500… | Other (stated, no rule matched) |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | terminated | Dec 6, 2019 | University of Miami | Investigator Decision | Investigator |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | Phase 2 | withdrawn | Dec 28, 2020 | Inhye Ahn | Bayer is no longer funding due to lack of accrual | Enrollment / accrual |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | Phase 1 | terminated | Jan 17, 2018 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and… | — | withdrawn | Jan 5, 2021 | Memorial Sloan Kettering Cancer Center | Lack of potential participants given the other treatment options currently available to people | Other (stated, no rule matched) |
| NCT04556084 | Blinatumomab Bridging Therapy for BALL | Phase 2 | terminated | Sep 21, 2020 | Michael Burke | poor accrual | Enrollment / accrual |
| NCT03286114 | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Phase 1 | terminated | Sep 18, 2017 | University of Michigan Rogel Cancer Center | Lack of patient population | Other (stated, no rule matched) |
| NCT03576547 | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or… | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | M.D. Anderson Cancer Center | The study was terminated early due to slow accrual and low level of interest both by the sponsor… | Enrollment / accrual |
| NCT05038644 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic… | Phase 1 | terminated | Sep 9, 2021 | Ehab L Atallah | Drug expired May 31, 2024. | Other (stated, no rule matched) |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched… | Phase 2 | terminated | Feb 14, 2012 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic… | Phase 1 | terminated | May 11, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Insufficient accrual over 12 mo period | Enrollment / accrual |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. A new study in CLL patients is planned. | Other (stated, no rule matched) |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA… | Phase 2 | terminated | Aug 3, 2018 | Memorial Sloan Kettering Cancer Center | Low accrual | Enrollment / accrual |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With…(R/R) | Phase 1 / Phase 2 | terminated | Jun 5, 2020 | Aprea Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's… | Phase 1 | terminated | Mar 28, 2019 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia… | Phase 1 | withdrawn | Mar 4, 2021 | M.D. Anderson Cancer Center | 0% Participants | Other (stated, no rule matched) |
| NCT05348889 | First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive… | Phase 1 / Phase 2 | terminated | Apr 27, 2022 | Chimagen Biosciences, Ltd | Sponsor's Research and Development strategy adjustment | Sponsor / business decision |
| NCT01743807 | Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia | Phase 1 | terminated | Dec 6, 2012 | Therapeutic Advances in Childhood Leukemia Consortium | SBI Biotech (supplier) decided to no longer support the study or GNKG168. | Other (stated, no rule matched) |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Phase 1 | terminated | May 14, 2021 | Lava Therapeutics | The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive… | Safety / toxicity |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R… | Phase 2 | terminated | Mar 12, 2020 | Zhejiang DTRM Biopharma | Despite the efforts of our dedicated team and initial progress, we were unable to secure the… | Funding |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic… | Phase 2 | terminated | Sep 10, 2019 | Fred Hutchinson Cancer Center | The federal funding period ended. The study was originally intended to be multi-site but was only… | Enrollment / accrual |
| NCT04029688 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of… | Phase 1 / Phase 2 | terminated | Jul 23, 2019 | Hoffmann-La Roche | Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed… | Efficacy / futility |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With…(UNITY-CLL) | Phase 3 | terminated | Nov 23, 2015 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT04526795 | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory… | Phase 1 | terminated | Aug 26, 2020 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT05350163 | T-cell Receptor α/β Depleted Donor Lymphocyte Infusion | Phase 1 | terminated | Apr 28, 2022 | Guenther Koehne | The study met criteria for stopping due to lack of efficacy per protocol specifications. | Efficacy / futility |
| NCT04340154 | Study of Sequential CAR-T Cell Treating Leukemia Children | Phase 2 | terminated | Apr 9, 2020 | Beijing Boren Hospital | ethic commitee decision | Other (stated, no rule matched) |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute… | Phase 1 | terminated | Sep 2, 2021 | Beijing Boren Hospital | ethic commitee decision | Other (stated, no rule matched) |
| NCT04762875 | MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in… | Phase 2 | terminated | Feb 21, 2021 | Ensoma | This study was voluntarily terminated due to a business decision not to proceed and not due to any… | Safety / toxicity |
| NCT04523623 | Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated… | N/A | withdrawn | Aug 21, 2020 | Washington University School of Medicine | Project canceled for other reason , describe: - Lack of enrollment Project canceled - lack of… | Enrollment / accrual |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Genmab | Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on… | Safety / toxicity |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | — | withdrawn | Aug 30, 2022 | Dana-Farber Cancer Institute | Funding for study was withdrawn | Funding |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | — | withdrawn | Nov 24, 2014 | Wake Forest University Health Sciences | No patients enrolled | Enrollment / accrual |
| NCT04322084 | Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With… | — | withdrawn | Mar 26, 2020 | St. Jude Children's Research Hospital | The study was activated at the onset of the COVID pandemic. At that time voluntary, non-therapeutic… | COVID-19 / pandemic |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 29, 2025source: clinicaltrials